Most Recent
Famed restaurant chain Momofuku has lost its challenge to the ‘Momofuku’ word mark of instant noodle giant Nissin, with IP Australia finding consumers were not likely to be deceived or confused because of the different goods and services provided by the two companies.
A group of Australia’s leading beef and dairy companies has failed to strike-out a suit alleging their genetic testing system for cattle infringes the patent of a US genomics company, with a judge rejecting objections to the phrase ‘further or in the alternative’.
Pharmaceutical giant Lundbeck has resolved its battle with Novartis unit Sandoz over top-selling drug Lexapro, a battle that has raged for years and across multiple courts.
Swiss aircraft manufacturer Pilatus has won discovery to pursue a possible copyright claim stemming from a Royal Australian Air Force flight simulator contract.
Radio manufacturer Hytera wants the High Court to hear its appeal of a finding that it misappropriated Motorola's source code in a case of "substantial industrial theft”.
An appeals court has rejected Chinese radio manufacturer Hytera’s challenge to a finding it misappropriated the source code of US mobile phone giant Motorola.
Indian drug maker Cipla has lost a challenge to the extension of Novo Nordisk’s patent for Victoza, with a judge rejecting an argument that extensions can be granted only for active ingredients.
As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta.